151 related articles for article (PubMed ID: 33517310)
1. Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events.
Takai R; Funakoshi Y; Suto H; Nagatani Y; Imamura Y; Toyoda M; Yakushijin K; Kiyota N; Harada KI; Yamashita K; Kakeji Y; Minami H
Anticancer Res; 2021 Feb; 41(2):1021-1026. PubMed ID: 33517310
[TBL] [Abstract][Full Text] [Related]
2. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
Sise ME; Wang Q; Seethapathy H; Moreno D; Harden D; Smith RN; Rosales IA; Colvin RB; Chute S; Cornell LD; Herrmann SM; Fadden R; Sullivan RJ; Yang NJ; Barmettler S; Wells S; Gupta S; Villani AC; Reynolds KL; Farmer J
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657813
[TBL] [Abstract][Full Text] [Related]
3. Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease.
Karim AF; Eurelings LEM; Bansie RD; van Hagen PM; van Laar JAM; Dik WA
Mediators Inflamm; 2018; 2018():6103064. PubMed ID: 29686532
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first.
Storwick JA; Tam H; Rosenbaum DG; Houghton K
Pediatr Rheumatol Online J; 2024 Apr; 22(1):49. PubMed ID: 38685034
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma.
Miura Y; Motoshima T; Anami T; Yano H; Mito R; Pan C; Urakami S; Kinowaki K; Tsukamoto H; Kurahashi R; Murakami Y; Yatsuda J; Fujiwara Y; Kamba T; Komohara Y
Microbiol Immunol; 2023 Jul; 67(7):345-354. PubMed ID: 36975091
[TBL] [Abstract][Full Text] [Related]
6. Correction: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37407238
[No Abstract] [Full Text] [Related]
7. Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors.
Liu W; Liu Y; Ma F; Sun B; Wang Y; Luo J; Liu M; Luo Z
Cancer Manag Res; 2021; 13():765-771. PubMed ID: 33536784
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors.
Rose LM; DeBerg HA; Vishnu P; Frankel JK; Manjunath AB; Flores JPE; Aboulafia DM
Front Oncol; 2020; 10():570752. PubMed ID: 33520695
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.
Li X; Yan S; Yang J; Wang Y; Lv C; Li S; Zhao J; Yang Y; Zhuo M; Wu N
Front Oncol; 2020; 10():574752. PubMed ID: 33585195
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer-A Systematic Review and Network Meta-Analysis.
Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Ohnishi T; Sagara H
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33561074
[TBL] [Abstract][Full Text] [Related]
11. Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.
Kelleher T; Cai J; Botwood NA; Labriola DF
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558277
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with
Shibaki R; Akamatsu H; Kato T; Nishino K; Okada M; Mitsudomi T; Wakuda K; Yoshimura K; Yamamoto N; Nakagawa K
Ther Adv Med Oncol; 2021; 13():1758835920987647. PubMed ID: 33613698
[TBL] [Abstract][Full Text] [Related]
16. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
[TBL] [Abstract][Full Text] [Related]
17. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331
Spigel DR; Vicente D; Ciuleanu TE; Gettinger S; Peters S; Horn L; Audigier-Valette C; Pardo Aranda N; Juan-Vidal O; Cheng Y; Zhang H; Shi M; Luft A; Wolf J; Antonia S; Nakagawa K; Fairchild J; Baudelet C; Pandya D; Doshi P; Chang H; Reck M
Ann Oncol; 2021 May; 32(5):631-641. PubMed ID: 33539946
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Cascone T; William WN; Weissferdt A; Leung CH; Lin HY; Pataer A; Godoy MCB; Carter BW; Federico L; Reuben A; Khan MAW; Dejima H; Francisco-Cruz A; Parra ER; Solis LM; Fujimoto J; Tran HT; Kalhor N; Fossella FV; Mott FE; Tsao AS; Blumenschein G; Le X; Zhang J; Skoulidis F; Kurie JM; Altan M; Lu C; Glisson BS; Byers LA; Elamin YY; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Roth JA; Antonoff MB; Kadara H; Haymaker C; Bernatchez C; Ajami NJ; Jenq RR; Sharma P; Allison JP; Futreal A; Wargo JA; Wistuba II; Swisher SG; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Sepesi B
Nat Med; 2021 Mar; 27(3):504-514. PubMed ID: 33603241
[TBL] [Abstract][Full Text] [Related]
19. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment.
Glode AE; May MB
Am J Health Syst Pharm; 2021 Apr; 78(9):769-780. PubMed ID: 33580648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
